Theragent to act as partner for CellVax’s Phase II cancer therapy

CellVax Therapeutics has selected Theragent as a manufacturing partner for its prostate cancer immunotherapy, which is entering a Phase II clinical trial.

A cell therapy contract development and manufacturing organisation (CDMO), Theragent will provide manufacturing and testing services for CellVax’s therapy FK-PC101.

For the manufacturing partnership, Theragent and CellVax commenced preparations, which include project planning and analytical method tech transfer.

Manufacturing services are set to start late this year, for which Theragent will deliver autologous cell-derived doses to support the early and pivotal trials of CellVax in the US.

Theragent chief operating officer Jeff Masten said: “Theragent is a newer CDMO, but we have assembled a team that brings decades of experience in the development and production of autologous cell-based products around the world.

“We are thrilled to support CellVax and their promising Phase II cancer vaccine candidate. Not only does this project fit seamlessly into our new, state-of-the-art cGMP manufacturing facility in Southern California, but the incredible science behind FK-PC101 is a harmonious fit with our company mission of delivering advanced medicines to cancer patients in need.”

In the trial, CellVax will examine and evaluate the way FK-PC101 reduces the recurrence of prostate-specific antigens (PSA) in patients with locally advanced prostate cancer following a radical prostatectomy (RP).

The cell-based autologous cancer vaccine FK-PC101 is intended for prostate cancer patients with a high recurrence risk after a prostatectomy.

CellVax CEO Fernando Kreutz said: “With our proprietary immunotherapy platform, we modify the patient’s tumour cells ex vivo, inducing them to behave as antigen-presenting cells, which are then formulated into a personalised cancer vaccine for that individual.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Share this article